Sun Pharmaceutical Industries Limited has released an investor presentation for December 2025, detailing its business operations, financial performance, and strategic focus areas. The presentation highlights the company's diversified revenue streams, with India Formulations contributing 33% and US Formulations 31% of FY25 sales. Sun Pharma reported impressive growth tracks across sales, EBITDA, Adjusted Net Profit, Operating Cash Flow, and Adjusted EPS over the FY10-FY25 period, with CAGRs ranging from 16% to 24%. Profitability metrics show strong performance, with Gross Margin reaching 79.3%, EBITDA Margin at 29.0%, and Adjusted Net Profit Margin at 22.8% in FY25. Return on Capital Employed (ROCE) and Return on Equity (ROE) also indicate robust financial health. The company operates globally across over 100 countries, with a significant presence in the US generics market (13th largest) and as the largest pharmaceutical company in India. Sun Pharma is expanding its presence in Emerging Markets and Rest of World regions, focusing on both Innovative Medicines and generics. Key financial highlights for Q2 FY26 show a 8.6% increase in Gross Sales to ₹144,052 million and a 14.9% rise in EBITDA to ₹45,271 million. For H1 FY26, Gross Sales grew by 9.3% to ₹281,913 million, with EBITDA up 17.0% to ₹88,287 million. Sun Pharma continues to invest in Research & Development, with R&D spend at 6.2% of sales for FY25. The company maintains a strong manufacturing infrastructure with 40 facilities globally, many approved by major regulatory authorities like the USFDA. Strategic focus areas include enhancing the share of innovative and branded business, focusing on complex generics, and maintaining leadership in competitive markets through continuous innovation and in-licensing opportunities.